Comparing Drug abelacimab relative to apixaban on venous

Recruiting

18 years - 99 years

All

10 participants needed

1 Location

Brief description of study

The purpose of this study is to see if patients taking the study drug abelacimab have fewer bleeding events compared to those taking apixaban. Participation will last for about 8 months (6 months of treatment and 2 months of follow up). Participants may be paid up to a total of $1000.00 (10 total visits).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: venous thromboembolism,VTE
Age: 18 years - 99 years
Gender: All

Updated on 04 Aug 2024. Study ID: 851767

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Comparing Drug abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)

Brief description of study

Eligibility of study

Find a site

Interested in the study